Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer RAINBO BLUE & TAPER
Endometrial CancerThis protocol tests de-escalated adjuvant treatment in patients with POLE-mutated or p53wt/NSMP (p53 wildtype/no specific molecular profile) early-stage endometrial cancer (EC). Patients may be enrolled in one of two sub-studies
* EN10.A/RAINBO BLUE: POLE-mutated EC
* EN10.B/TAPER: p53 wildtype / NSMP EC
null
Conditions de participation
-
Sexe:
FEMALE -
Âges admissibles:
18 and up
Critères de participation
Inclusion Criteria:
* Patients must have had surgery consisting of hysterectomy and bilateral salpingo-oophorectomy. Lymph node dissection can be performed as per institutional standards. There must be no macroscopic residual disease after surgery.
* Patients must have histologically confirmed Stage I to III endometrial carcinoma which can be endometrioid, serous, clear cell, un/dedifferentiated, carcinosarcoma or mixed.
* Patients' Eastern Cooperative Group (ECOG) performance status must be 0, 1, or 2.
* HIV-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial.
* Patients' age must be ≥ 18 years.
* Patient consent must be appropriately obtained in accordance with applicable local and regulatory requirements.
* Patient is able (i.e. sufficiently fluent) and willing to complete the patient-reported outcomes (PRO) questionnaires in either English, French or a validated language
* Patients must be accessible for treatment and follow-up. Patients enrolled on this trial must be treated and followed at the participating centre
* Protocol treatment is to begin within 10 weeks of hysterectomy/bilateral salpingo-oophorectomy
Exclusion Criteria:
* Prior Neoadjuvant chemotherapy for current endometrial cancer diagnosis.
* Prior pelvic radiation.
* Patients with a history of other malignancies, except: carcinoma in-situ without evidence of invasive disease when resected, adequately treated non-melanoma skin cancer, or other tumours curatively treated with no evidence of disease for ≥ 5 years.
* Clinical evidence of distant metastasis as determined by pre-surgical or post-surgical imaging (CT scan of chest, abdomen and pelvis or whole-body PET-CT scan)
* Patients with a documented positive surgical margin.
* Patients with a documented positive peritoneal washings, if performed.
Lieu de l'étude
BCCA - Prince George
BCCA - Prince GeorgePrince George, British Columbia
Canada
Contactez l'équipe d'étude
Allison Ye
250 645-7300Trillium Health Partners - Credit Valley Hospital
Trillium Health Partners - Credit Valley HospitalMississauga, Ontario
Canada
Contactez l'équipe d'étude
Katherine Pulman
905 813-1100The Jewish General Hospital
The Jewish General HospitalMontreal, Quebec
Canada
Contactez l'équipe d'étude
Susie K.S. Lau
514 340-8222BCCA - Kelowna
BCCA - KelownaKelowna, British Columbia
Canada
Contactez l'équipe d'étude
Hamid Raziee
Verspeeten Family Cancer Centre
Verspeeten Family Cancer CentreLondon, Ontario
Canada
Contactez l'équipe d'étude
Lucas Mendez
519 685-8600CHUM-Centre Hospitalier de l'Universite de Montreal
CHUM-Centre Hospitalier de l'Universite de MontrealMontreal, Quebec
Canada
Contactez l'équipe d'étude
Maroie Barkati
514 890-8254Cross Cancer Institute
Cross Cancer InstituteEdmonton, Alberta
Canada
Contactez l'équipe d'étude
University Health Network
University Health NetworkToronto, Ontario
Canada
Contactez l'équipe d'étude
BCCA - Victoria
BCCA - VictoriaVictoria, British Columbia
Canada
Contactez l'équipe d'étude
London Health Sciences Centre Research Inc.
London Health Sciences Centre Research Inc.London, Ontario
Canada
Contactez l'équipe d'étude
Lucas Mendez
519 685-8600Arthur J.E. Child Comprehensive Cancer Centre
Arthur J.E. Child Comprehensive Cancer CentreCalgary, Alberta
Canada
Contactez l'équipe d'étude
Tien Phan
403 521-3926BCCA - Vancouver
BCCA - VancouverVancouver, British Columbia
Canada
Contactez l'équipe d'étude
Jessica McAlpine
604 877-6000Odette Cancer Centre
Odette Cancer CentreToronto, Ontario
Canada
Contactez l'équipe d'étude
Helen MacKay
416 480-5145CIUSSS de l'Estrie - Centre hospitalier
CIUSSS de l'Estrie - Centre hospitalierSherbrooke, Quebec
Canada
Contactez l'équipe d'étude
Mathieu Viau
- Étude parrainée par
- Canadian Cancer Trials Group
- Participants recherchés
- Plus d'informations
- ID de l'étude:
NCT05640999